Some good news for the UK industry in turbulent times is always welcome, and several announcement this month showed us why the biotech sector in the country is looking extremely promising g
Over the years, many hands have been wrung over clinical trial recruitment – low participation rates are common and can bring down studies before they even get a chance to begin.
Ahead of eyeforpharma Philadelphia 2019, Sonal Bhatia, Pfizer’s vice president, North America medical lead, rare disease talked to us about the importance of collaboration and RWE to he
For episode 7 of the pharmaphorum podcast I spoke to Ipsen’s Philippe Picaut about neurotoxin research, with a particular focus on Botulinum neurotoxins.